Intra-Cellular Therapies (ITCI) Sinks 69% as Trading Resumes

September 28, 2016 4:33 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Intra-Cellular Therapies (NASDAQ: ITCI) sinks 68.7% as trading resumes following trial failure.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Hot FDA News, Trader Talk, Trading Halts

Related Entities

The Children's Investment Fund (TCI)

Add Your Comment